IP portfolio summary:
- >50 granted or allowed US and international patents
- Compositions of matter for TIL products
- Methods of treatment in a broad range of cancers
- Manufacturing processes
- >700 patents and applications worldwide, including major pharmaceutical markets
Streamlined 22-day GMP manufacturing process
Proprietary manufacturing processes and expansion methods for TIL from:
- Tumor
- Marrow infiltrating lymphocytes
- Peripheral blood lymphocytes
- Frozen tumor technologies
- Remnant TIL and digest processes
- Combination of TIL and ICIs including PD-1 antibodies
- Methods of treating patient subpopulations
- IL-2 variants and regimens
TIL products and compositions: Gen 2, Gen 3, use of co-stimulatory molecules, selection of TIL, stable and transient genetic modifications, cryopreservation
Proprietary manufacturing processes and expansion methods for TIL from:
- Tumor
- Marrow infiltrating lymphocytes
- Peripheral blood lymphocytes
- Frozen tumor technologies
- Remnant TIL and digest processes
- Combination of TIL and ICIs including PD-1 antibodies
- Methods of treating patient subpopulations
- IL-2 variants and regimens
TIL products and compositions: Gen 2, Gen 3, use of co-stimulatory molecules, selection of TIL, stable and transient genetic modifications, cryopreservation
Broad, Iovance-owned IP around TIL therapy
Iovance owns more than 40 US patents related to TIL therapy, including patents directed to compositions and methods of treatment in a broad range of cancers, such as US Patent Nos. 10,130,659; 10,166,257; 10,272,113; 10,363,273; 10,398,734; 10,420,799; 10,463,697; 10,517,894; 10,537,595; 10,639,330; 10,646,517; 10,653,723; 10,695,372; 10,894,063; 10,905,718; 10,918,666; 10,925,900; 10,933,094; 10,946,044; 10,946,045; 10,953,046; 10,953,047; 11,007,225; 11,007,226; 11,013,770; 11,026,974; 11,040,070; 11,052,115; 11,052,116; 11,058,728; 11,083,752; 11,123,371; 11,141,438; 11,168,303; 11,168,304; 11,179,419; 11,202,803; 11,202,804; 11,220,670; 11,241,456; 11,254,913; 11,266,694; 11,273,180; 11,273,181; 11,291,687; 11,304,979; 11,304,980; 11,311,578; 11,337,998; 11,344,579; 11,344,580; 11,344,581; 11,351,197; 11,351,198; 11,351,199; 11,364,266; 11,369,637; and 11,384,337.
Iovance also owns US patents covering methods of manufacturing TIL and TIL manufactured from a tumor digest and the use thereof, such as US Patent Nos. 11,007,225; 11,007,226; 11,052,115; 11,052,116; 11,058,728; 11,083,752; 11,123,371; 11,141,438; 11,179,419; 11,202,803; 11,202,804; 11,241,456; 11,254,913; 11,266,694; 11,273,180; 11,273,181; 11,291,687; 11,304,979; 11,337,998; 11,344,579; and others.
US Patent No. 11,058,728 specifically covers a method of treatment using expanded TILs manufactured from a tumor digest where the expansion steps through the step of cryopreservation of the infusion bag having a harvested TIL population are performed within about 24 days. US Patent No. 11,123,371 specifically covers a cryopreserved TIL composition comprising expanded TILs manufactured from a cryopreserved tumor digest where the expansion steps through the step of cryopreservation of the infusion bag having a harvested TIL population are performed within about 24 days. US Patent No. 11,141,438 specifically covers an expanded population of TILs manufactured from a cryopreserved tumor digest where the expansion steps through the harvest step are performed within about 24 days. US Patent No. 11,179,419 specifically covers a method for expanding TILs from a cryopreserved tumor digest where the expansion steps through the step of cryopreservation of the infusion bag having a harvested TIL population are performed within about 24 days.
Iovance holds an exclusive license from NIH of certain rights under U.S. Patent Nos. 11,077,182; 11,331,385; 11,338,032; and 11,376,318; covering TILs manufactured from T-cells expanded from HPV+ tumor fragments and methods of treating HPV+ cancers in a patient with TILs manufactured from T-cells expanded from HPV+ tumor fragments obtained from the patient.
Furthermore, Iovance owns US patents covering the use of the combination of TIL therapy and an anti-PD-1 antibody, such as US Patent No. 10,272,113, or an anti-PD-L1 antibody, such as US Patent No. 11,013,770.
OUR PATENT PORTFOLIO ALSO INCLUDES PATENTS AND PATENT APPLICATIONS RELATING TO:
- Frozen tumor-based TIL technologies
- Remnant TIL and digest TIL compositions and methods
- Use of co-stimulatory and T cell modulating molecules in TIL therapy and manufacturing
- Stable and transient genetically-modified TIL therapies
- Methods of using immune–checkpoint inhibitors in combination with TIL therapies
- TIL selection technologies
- Methods of treating patient subpopulations
US patent/
application information for Iovance clinical products
Lifileucel (TIL)
Patients with metastatic melanoma or cervical cancer
US 10,894,063;
US 10,398,734;
US 10,537,595;
US 10,695,372;
US 10,653,723;
US 11,337,998;
US 11,344,579
US 10,166,257;
US 10,130,659;
US 10,272,113;
US 10,463,697;
US 10,363,273;
US 10,646,517;
US 10,905,718;
US 11,202,803;
US 11,241,456;
US 10,953,046;
US 10,946,044;
US 10,953,047;
US 10,933,094;
US 10,946,045;
US 10,925,900;
US 11,013,770;
US 11,202,804;
US 11,273,181
US 10,420,799;
US 10,639,330;
US 10,918,666;
US 11,273,180;
US 11,291,687;
US 11,304,979
Lifileucel or tumor digest TIL
Patients with metastatic melanoma or cervical cancer
US 11,337,998;
US 11,344,579
US 11,202,803;
US 11,202,804;
US 11,241,456;
US 11,273,181
US 11,273,180;
US 11,291,687;
US 11,304,979
LN-145 (TIL)
Patients with metastatic melanoma, HNSCC, or NSCLC
US 10,894,063;
US 10,398,734;
US 10,537,595;
US 10,695,372;
US 10,653,723;
US 11,337,998;
US 11,344,579
US 10,166,257;
US 10,130,659;
US 10,272,113;
US 10,463,697;
US 10,363,273;
US 10,646,517;
US 10,905,718;
US 10,953,046;
US 10,946,044;
US 10,953,047;
US 10,933,094;
US 10,946,045;
US 10,925,900;
US 11,013,770;
US 11,202,803;
US 11,202,804;
US 11,241,456;
US 11,273,181
US 10,420,799;
US 10,639,330;
US 10,918,666;
US 11,291,687;
US 11,304,979
Gen 3 TIL
Patients with metastatic melanoma, HNSCC, or NSCLC
US 10,894,063;
US 10,398,734;
US 10,537,595;
US 10,695,372;
US 10,653,723;
US 11,337,998;
US 11,344,579
US 10,166,257;
US 10,130,659;
US 10,272,113;
US 10,463,697;
US 10,363,273;
US 10,646,517;
US 10,905,718;
US 11,202,803;
US 11,241,456;
US 10,953,046;
US 10,946,044;
US 10,953,047;
US 10,933,094;
US 10,946,045;
US 10,925,900;
US 11,013,770;
US 11,202,804;
US 11,273,181
US 10,420,799;
US 10,639,330;
US 10,918,666;
US 11,168,304;
US 11,273,180;
US 11,291,687;
US 11,304,979
IOV-2001 (PBL)
Patients with CLL or SLL
WO 2020/180733 A1;
US 2020/0224161 A1;
US 2020/0347350 A1
WO 2020/180733 A1;
US 2020/0224161 A1;
US 2020/0347350 A1
WO 2020/180733 A1;
US 2020/0224161 A1;
US 2020/0347350 A1
IOV-4001 (PD1 KO TIL)
Patients with metastatic melanoma or NSCLC
US 11,384,337
*Subject to FDA approval.
CLL=chronic lymphocytic leukemia; HNSCC=head and neck squamous cell carcinoma; HPV=human papilloma virus; ICI=immune checkpoint inhibitors; IL-2=interleukin 2; IP=intellectual property; NMA-LD=non-myeloablative lymphoid depletion; NSCLC=non-small-cell lung cancer; PBL=peripheral blood lymphocytes; PD-L1=programmed cell death protein-1; SLL=small lymphocytic leukemia.
This site may contain information on an investigational agent(s) or investigational uses of approved agent(s) that has not been reviewed or approved by the FDA or other regulatory authorities. Iovance does not endorse or recommend any unapproved use of its products. Please refer to product prescribing information, where available.